Skip to content

Clinical observation and pharmacodynamic mechanism study on the treatment of chronic atrophic gastritis with Jinbuhuan Jianweijiedu Decoction

Clinical observation and pharmacodynamic mechanism study on the treatment of chronic atrophic gastritis with Jinbuhuan Jianweijiedu Decoction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000384
Enrollment
Unknown
Registered
2024-09-05
Start date
2023-03-23
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic atrophic gastritis

Interventions

Control group:Folic acid tablets
treatment group:Jinbuhuan Jianweijiedu Decoction

Sponsors

GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINEHAINAN HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. meet the western medical diagnostic criteria for chronic atrophic gastritis; 2. meet the Chinese medicine diagnostic criteria for chronic atrophic gastritis with cold and heat mismatch; 3. be aged between 18 and 70 years old; 4. be able to speak and read Chinese and have communicated and filled in the questionnaire; 5. voluntarily participate in this study and sign an informed consent form

Exclusion criteria

Exclusion criteria: 1. endoscopic findings of advanced intraepithelial neoplasia within the gastric mucosa pathologically diagnosed malignant lesions and organic diseases of the gastrointestinal tract; 2. confusion dementia various psychiatric disorders severe neurosis and unwillingness to co-operate; 3. having severe primary cardiovascular lesions hepatic lesions renal lesions haematological lesions pulmonary diseases autoimmune system diseases or serious diseases affecting his/her survival such as tumours or AIDS 4. Pregnant or breastfeeding women; 5. Cognitive or other impairments (e.g. vision) that would interfere with the participant's ability to complete the self-report; 6. Allergic or multi-drug sensitivities or allergies to drugs prescribed for observation; 7. Patients who are participating in a clinical trial of another drug or who are participating in a clinical trial of another drug within 4 weeks of the trial; and 8. Persons who based on the participant's current medical or psychological status the investigator has good reason to believe that it is inappropriate to proceed with the study.

Design outcomes

Primary

MeasureTime frame
Pathohistological indicators;

Secondary

MeasureTime frame
Measurement of serum inflammatory factor levels;Serological indicators of gastric function;Chinese Medicine Symptom Score;gastroscopy examination;

Countries

China

Contacts

Public ContactCai Min

GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINEHAINAN HOSPITAL

simontcm@sohu.com13807666333

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026